XHKG
1951
Market cap1.10bUSD
Aug 08, Last price
3.20HKD
1D
0.63%
1Q
8.11%
IPO
-63.39%
Name
Jinxin Fertility Group Ltd
Chart & Performance
P/E
27.91
P/S
2.81
EPS
0.10
Div Yield, %
1.86%
Shrs. gr., 5y
4.27%
Rev. gr., 5y
11.27%
Revenues
2.81b
+0.81%
Net income
283m
-17.88%
CFO
629m
-8.08%
Dividend
Jun 27, 20240.0595 HKD/sh
Profile
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 2,811,596 0.81% | 2,788,910 17.95% | 2,364,479 28.59% | ||||||
Cost of revenue | 2,370,014 | 2,308,436 | 2,079,113 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 441,582 | 480,474 | 285,366 | ||||||
NOPBT Margin | 15.71% | 17.23% | 12.07% | ||||||
Operating Taxes | 118,420 | 117,285 | 36,375 | ||||||
Tax Rate | 26.82% | 24.41% | 12.75% | ||||||
NOPAT | 323,162 | 363,189 | 248,991 | ||||||
Net income | 283,099 -17.88% | 344,723 184.60% | 121,124 -64.36% | ||||||
Dividends | (10,504) | (158,676) | |||||||
Dividend yield | 0.11% | 0.84% | |||||||
Proceeds from repurchase of equity | 999,586 | 583,698 | |||||||
BB yield | -10.91% | -3.08% | |||||||
| Debt | |||||||||
Debt current | 1,441,046 | 976,641 | 1,717,933 | ||||||
Long-term debt | 1,608,808 | 2,151,315 | 2,609,831 | ||||||
Deferred revenue | 984,226 | ||||||||
Other long-term liabilities | 1,234,225 | 1,290,142 | (2,170,589) | ||||||
Net debt | 1,896,770 | 2,003,480 | 2,795,519 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 629,201 | 684,484 | 541,740 | ||||||
CAPEX | (139,904) | (173,568) | (959,393) | ||||||
Cash from investing activities | (293,271) | (375,037) | (1,377,837) | ||||||
Cash from financing activities | (458,291) | (950,449) | 460,142 | ||||||
FCF | 175,705 | 334,925 | (1,353,203) | ||||||
| Balance | |||||||||
Cash | 570,821 | 852,900 | 1,401,248 | ||||||
Long term investments | 582,263 | 271,576 | 130,997 | ||||||
Excess cash | 1,012,504 | 985,030 | 1,414,021 | ||||||
Stockholders' equity | 10,354,187 | 1,935,916 | 1,329,979 | ||||||
Invested Capital | 13,290,885 | 13,197,954 | 11,559,794 | ||||||
ROIC | 2.44% | 2.93% | 2.38% | ||||||
ROCE | 3.09% | 3.39% | 2.03% | ||||||
| EV | |||||||||
Common stock shares outstanding | 2,719,182 | 2,735,787 | 2,624,469 | ||||||
Price | 2.69 -19.70% | 3.35 -53.54% | 7.21 -17.22% | ||||||
Market cap | 7,314,600 -20.19% | 9,164,886 -51.57% | 18,922,421 -13.25% | ||||||
EV | 9,291,138 | 11,655,760 | 22,286,287 | ||||||
EBITDA | 719,383 | 765,202 | 546,760 | ||||||
EV/EBITDA | 12.92 | 15.23 | 40.76 | ||||||
Interest | 79,641 | 71,853 | |||||||
Interest/NOPBT | 16.58% | 25.18% | |||||||